GALT Galectin Therapeutics Inc.

+0.01  (0%)
Previous Close 2.35
Open 2.36
Price To book 25.27
Market Cap 80.39M
Shares 34,064,000
Volume 136,928
Short Ratio 1.89
Av. Daily Volume 545,797

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released March 6, 2017.
Plaque psoriasis
Phase 2a primary endpoint not met - September, 27 2016.
Nonalcoholic steatohepatitis (NASH)
Phase 2a interim data released May 2016
moderate-to-severe plaque psoriasis.
Phase 2b top-line data due December 2017.
Non-alcoholic steatohepatitis (NASH) with cirrhosis

Latest News

  1. Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update
  2. Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease
  3. Can The Uptrend Continue for Galectin Therapeutics (GALT)?
  4. Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
  5. Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings?
  6. Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings?
  7. Edward Lifesciences (EW) Q1 Earnings: A Surprise in Store?
  8. Can Mead Johnson (MJN) Spring a Surprise in Q1 Earnings?
  9. ResMed (RMD) Q3 Earnings: Disappointment in the Cards?
  10. IDEXX Laboratories (IDXX) Q1 Earnings: Surprise in Store?
  11. Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017
  12. Can Illumina (ILMN) Spring a Surprise this Earnings Season?
  13. 5 Drug Stocks That Could Be Big Winners this Earnings Season
  14. Integra LifeSciences (IART) Q1 Earnings: A Beat in Store?
  15. GNC Holdings (GNC) Q1 Earnings: Disappointment in Store?
  16. Galectin Therapeutics and Axovant Sciences See Stocks Rise on Investor Optimism
  17. Galectin Therapeutics (GALT) Looks Good: Stock Jumps 16.7%
  18. Akari Therapeutics, Galectin Therapeutics Receive Positive Financial News
  19. Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst'